Literature DB >> 25664083

The application of vWF/ADAMTS13 in essential hypertension.

Wei-Hong Ma1, Lin Sheng1, Hui-Ping Gong1, Lin-Lin Guo1, Qing-Hua Lu1.   

Abstract

BACKGROUND: Plasma von Willebrand factor (vWF), a key player in hemostasis and thrombosis, is released from endothelial cells during inflammation. Hypertension, a progressing in chronic inflammation and cardiovascular syndrome with various causes, results in functional and structural changes of heart and arterial vessels. However little information is available on LA changes during hypertension. Left atrial (LA) enlargement is associated with significant cardiovascular morbidity and mortality. The aim of this study was to explore the relationship between LA enlargement and thromboembolic risk in essential hypertensive patients with Af without any signs of clinical thrombotic disease or previous stroke.
METHODS: The relationship between Plasma vWF, ADAMTS13 and left atrial diameter (LAD), left atrial volume (LAV), left atrial volume index (LAVi) were evaluated in essential hypertensive group included 105 patients (55 patients with nonvalvular atrial fibrillation (AF) and 50 patients with normal sinus rhythm (NSR)).
RESULTS: The study demonstrated that vWF, vWF/ADAMT13, LAD, LAV and LAVi were increased significantly (P < 0.01) but ADAMTS13: Ag was decreased significantly (P < 0.01) in the hypertensive with AF group compared with NSR group.
CONCLUSION: vWF/ADAMTS13 were positively correlated with LAD, LAV and LAVi (P < 0.01). Increased vWF and vWF/ADAMTS13 is associated with LAD, LAV and LAVi in essential hypertension. The study suggests it played a positive role of vWF and vWF/ADAMTS13 in the progressing major adverse cardiovascular events (MACE) in essential hypertensive patients with LA enlargement.

Entities:  

Keywords:  Echocardiography; essential hypertension; left atrium; vWF-ADAMTS13

Year:  2014        PMID: 25664083      PMCID: PMC4307530     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

1.  Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage.

Authors:  M Fukuchi; J Watanabe; K Kumagai; Y Katori; S Baba; K Fukuda; T Yagi; A Iguchi; H Yokoyama; M Miura; Y Kagaya; S Sato; K Tabayashi; K Shirato
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

2.  Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.

Authors:  C A Siedlecki; B J Lestini; K K Kottke-Marchant; S J Eppell; D L Wilson; R E Marchant
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  A new automated screening assay for the diagnosis of von Willebrand disease.

Authors:  Raneem O Salem; Elizabeth M Van Cott
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

5.  Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging.

Authors:  Peter Bernhardt; Harald Schmidt; Christoph Hammerstingl; Berndt Lüderitz; Heyder Omran
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

6.  The impact of acute atrial fibrillation on the prothrombotic state in patients with essential hypertension.

Authors:  Jianping Hou; Yonggang Liang; Xiaobo Gai; Hueimin Zhang; Xiangyue Yang; Xiaopeng Lan; Weixing Zheng; Mingfang Huang
Journal:  Clin Biochem       Date:  2010-07-23       Impact factor: 3.281

7.  Diastolic dysfunction and left atrial volume: a population-based study.

Authors:  Allison M Pritchett; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer; Barry L Karon; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2005-01-04       Impact factor: 24.094

8.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

9.  von Willebrand factor: measuring its antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems.

Authors:  B E Fischer; K B Thomas; F Dorner
Journal:  Thromb Res       Date:  1998-07-01       Impact factor: 3.944

10.  Smoking is associated with the incidence of AMS: a large-sample cohort study.

Authors:  Pan Song; Ji-Hang Zhang; Jun Qin; Xu-Bin Gao; Jie Yu; Xu-Gang Tang; Cai-Fa Tang; Lan Huang
Journal:  Mil Med Res       Date:  2014-07-23
View more
  2 in total

1.  Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease.

Authors:  Mariya H Apostolova; Craig D Seaman; Diane M Comer; Jonathan G Yabes; Margaret V Ragni
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-21       Impact factor: 2.389

Review 2.  Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review.

Authors:  Alexander Weymann; Anton Sabashnikov; Sadeq Ali-Hasan-Al-Saegh; Aron-Frederik Popov; Seyed Jalil Mirhosseini; William L Baker; Mohammadreza Lotfaliani; Tong Liu; Hamidreza Dehghan; Senol Yavuz; Michel Pompeu Barros de Oliveira Sá; Jae-Sik Jang; Mohamed Zeriouh; Lei Meng; Fabrizio D'Ascenzo; Abhishek J Deshmukh; Guiseppe Biondi-Zoccai; Pascal M Dohmen; Hugh Calkins; Integrated Meta-Analysis Of Cardiac Cardiac Surgery And Cardiology-Group Imcsc-Group
Journal:  Med Sci Monit Basic Res       Date:  2017-03-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.